Skillsoft Enters Agreement to Sell SumTotal to Cornerstone for $200 Million
Expected to be accretive to Skillsoft’s bookings and revenue growth Sharpens focus on higher growth…
News
AIDP’s Andy Khawaja is “The Man Behind Limitless New AI Technology”
LOS ANGELES–(BUSINESS WIRE)–Artificial Intelligence Defense Platform, a technology start-up creating AI technology for a safer,…
Getac’s Introduces New X600 Fully Rugged Mobile Workstation – Formidable Performance and Connectivity in a Single Solution for Today’s Mission Critical Ops
IRVINE, Calif.–(BUSINESS WIRE)–Getac Technology Corporation, a leading producer of rugged technology today announced the launch…
Sion Power’s Lithium Metal Battery Technology Assessed by Leading Independent Industry Expert
TUCSON, Arizona–(BUSINESS WIRE)–#automotive–Sion Power Corporation (Sion Power), a leader in next-generation rechargeable batteries, released the…
Signature Bank Appoints Five Private Client Banking Teams and Names Group Director to Existing Team Throughout the Metropolitan New York Marketplace
NEW YORK–(BUSINESS WIRE)–Signature Bank (Nasdaq: SBNY), a New York-based, full-service commercial bank, announced today the…
Double accolade for TCG at global security awards
Beaverton, OR, USA, June 13, 2022 – Cybersecurity experts and Amy Nelson and Kathleen McGill,…
FullCircl Releases Company Group Explorer
A Unique Way to Visualise and Explore Company Hierarchies for Easier Onboarding and Risk Management…
Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol
Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol. Villepinte (France), June…
Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
Sanofi–GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron Next-generation…
Bone Therapeutics to host Extraordinary General Meeting on 13 July 2022
REGULATED INFORMATION Preliminary documents for the Extraordinary General Meeting have been made available on company’s…
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to…
LBank Exchange Will List Kona Summit Platform Coin (KSPC) on June 13, 2022
Internet City, Dubai–(Newsfile Corp. – June 13, 2022) – LBank Exchange, a global digital asset…
LBank Exchange Will List NASDAC Crypto Coin (NDCC) on June 14, 2022
Internet City, Dubai–(Newsfile Corp. – June 13, 2022) – LBank Exchange, a global digital asset…
Lendlease commences construction on 100 MW data centre campus in Japan for Princeton Digital Group
TOKYO, Jun 13, 2022 – (ACN Newswire) – Lendlease and Princeton Digital Group (PDG) today…
Malaysian Genomics Resource Centre Berhad Gets Affected Issuer Status Uplifted
PETALING JAYA, Malaysia, Jun 13, 2022 – (ACN Newswire) – Malaysian Genomics Resource Centre Berhad…
Lunar (LNR) Is Now Available for Trading on LBank Exchange
Internet City, Dubai–(Newsfile Corp. – June 12, 2022) – LBank Exchange, a global digital asset…
Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma
Data show an overall response rate (ORR) of 64% and clinical benefit rate (CBR) of…
Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency
Investigational phase 3 data for Sogroya® (somapacitan) injection in children with growth hormone deficiency presented…
Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic…
Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic…